Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(OP:
SDZNY
)
35.81
+0.52 (+1.47%)
Streaming Delayed Price
Updated: 3:53 PM EDT, May 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
55,476
Open
35.50
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
35.29
Today's Range
35.29 - 35.90
52wk Range
25.71 - 37.71
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Sandoz reports first quarter 2024 sales
May 07, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
April 30, 2024
Sandoz resolves patent litigation with Amgen, paving the way for the launch of denosumab biosimilars Jubbonti and Wyost.
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Performance
YTD
+12.33%
+12.33%
1 Month
+17.60%
+17.60%
3 Month
+12.82%
+12.82%
6 Month
+19.89%
+19.89%
1 Year
+35.03%
+35.03%
More News
Read More
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
April 30, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
April 30, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
April 22, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
March 21, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz reports fourth quarter 2023 sales and full-year 2023 results
March 13, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz receives FDA approval for first and only denosumab biosimilars
March 05, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz announces nominations to the Board of Directors and leadership change
March 05, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
March 04, 2024
From
Sandoz Group
Via
GlobeNewswire
Generic/Biosimilar Player Sandoz Settles US Price Fixing Case For $265M
February 29, 2024
Via
Benzinga
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
February 29, 2024
From
Sandoz Group
Via
GlobeNewswire
Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?
January 22, 2024
Via
Benzinga
Venue Turmoil: Pharma Companies Oppose States' Bid to Relocate Price-Fixing Cases
December 04, 2023
Via
Benzinga
Novartis Q3: Earnings Beat, Raised Operating Profit Outlook & More
October 24, 2023
Via
Benzinga
Topics
Earnings
Exposures
Financial
Eli Lilly, McKesson, Novartis Flash Promising Chart Action
October 09, 2023
Via
MarketBeat
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.